FDA-approved HIV drugs targeting reverse transcriptase (RT) may reduce Alzheimer's risk by blocking similar enzymatic activity in the aging brain. Scientists discovered unexpected RT activity in neurons of healthy and Alzheimer's brains, tracing it to truncated LINE1 elements--ancient genetic sequences capable of copying themselves via RT.
FDA-approved HIV drugs targeting reverse transcriptase (RT) may reduce Alzheimer's risk by blocking similar enzymatic activity in the aging brain. Scientists discovered unexpected RT activity in neurons of healthy and Alzheimer's brains, tracing it to truncated LINE1 elements--ancient genetic sequences capable of copying themselves via RT.
Share this Article
Recommended